Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 1013

NOTICE by Amgen Inc. of Intent to Present Live Testimony of Dr. Strickland in Response to Roche's Deposition Designations (Gottfried, Michael)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 1013

Case 1:05-cv-12237-WGY

Document 1013

Filed 09/06/2007

Page 1 of 4

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) ) ) Plaintiff, ) ) v. ) ) ) F. HOFFMANN-LAROCHE ) LTD., a Swiss Company, ROCHE ) DIAGNOSTICS GmbH, a German ) Company and HOFFMANN LAROCHE ) INC., a New Jersey Corporation, ) ) Defendants. ) __________________________________________) AMGEN INC.,

Civil Action No.: 05-12237 WGY

AMGEN INC.'S NOTICE OF INTENT TO PRESENT LIVE TESTIMONY OF DR. STRICKLAND IN RESPONSE TO ROCHE'S DEPOSITION DESIGNATIONS

Notice of Intent to withdraw Strickland counterdesignations.doc

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 1013

Filed 09/06/2007

Page 2 of 4

Amgen hereby provides notice of its intent to provide live counter testimony in response to Roche's deposition designations of Dr. Strickland. The Court has previously held that this procedure is acceptable: "[I]f it's an Amgen person, we would like to put the person on, not just read other portions of the deposition. I like that. That makes good sense to me. ... Of course, you're limited to what they put on in the deposition as the scope of examination of adverse witnesses is always so limited. But I like that."1 Amgen understands this procedure to allow the witness to testify live to lines of questioning that fall within the scope of the direct examination questions posed via deposition. Amgen hereby withdraws its general objection to Roche's use of deposition testimony for Dr. Strickland. However, Amgen maintains its specific objections to particular testimony designated by Roche. Amgen also withdraws its counter-designations for Dr. Strickland. Amgen presumes that Roche will withdraw its counters to Amgen's counter-designations as well, and will provide Roche with a revised copy of the 3/9/07 Strickland transcript for Roche's review. After receiving approval from Roche on this revised transcript, Amgen will provide a copy to the Court.

1

09/04/07 Trial Tr. at 27:18 ­ 28:7. 1

783709_1

Case 1:05-cv-12237-WGY

Document 1013

Filed 09/06/2007

Page 3 of 4

Respectfully Submitted, AMGEN INC., By its attorneys, ______________________________________ D. DENNIS ALLEGRETTI (BBO#545511) MICHAEL R. GOTTFRIED (BBO#542156) PATRICIA R. RICH (BBO#640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: [phone] Facsimile: [phone] LLOYD R. DAY, JR. (pro hac vice) DAY CASEBEER MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: [phone] Facsimile: [phone] WILLIAM GAEDE III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: [phone] Facsimile: [phone] KEVIN M. FLOWERS (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago IL 60606 Telephone: [phone] Facsimile: [phone]

Of Counsel: STUART L. WATT WENDY A. WHITEFORD MONIQUE L. CORDRAY DARRELL G. DOTSON KIMBERLIN L. MORLEY ERICA S. OLSON AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 [phone]

September 6, 2007

783709_1

2

Case 1:05-cv-12237-WGY

Document 1013

Filed 09/06/2007

Page 4 of 4

CERTIFICATE OF SERVICE I hereby certify that this document, filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing and paper copies will be sent to those indicated as non-registered participants on the above date. /s/ Michael R. Gottfried Michael R. Gottfried

783709_1

3